Cognitive-behavioral treatment with behavioral activation for smoking cessation: Randomized controlled trial
Martínez-Vispo, C. ; Rodríguez-Cano, R. ; López-Durán, A. ; Senra, C. ; Fernández Del Río, E. (Universidad de Zaragoza) ; Becoña, E.
Resumen: Introduction: Behavioral Activation is a behavioral-based treatment that has been proposed as suitable for smoking cessation, as it simultaneously addresses reinforcement-related variables and also mood management. The aim of this study was to compare the effects of a cognitivebehavioral smoking cessation treatment with components of behavioral activation (SCBSCT-BA) with a standard cognitive-behavioral treatment (SCBSCT), and a wait-list control group (WL).
Method: The sample was comprised of 275 adults smokers (61.4% females, mean age = 45.36, SD = 10.96). After baseline assessment sessions, participants were randomized (ratio: 2.2.1.) to SCBSCT-BA, SCBSCT, or WL. Active groups received 8 weekly 1-hour face-to-face group sessions. Biochemically verified smoking abstinence and depressive symptoms were assessed at the end of treatment, and at 3-, 6-, and 12-month follow-ups.
Results: Significant treatment effects in 7-dayspoint prevalence abstinence rates were found for both active groups at the end of treatment. Abstinence rates at 12-months follow-up were 30% for SCBSCT-BA, and 18% for SCBSCT. Using Multiple Imputation for missing data, regression analysis showed significantly greater ORs for the SCBSCT-BA condition (vs. SCBSCT) at the end of treatment and at 3-months follow-up. At 6-, and 12-months follow-ups, ORs for the SCBSCT-BA condition, although greater, did not reach statistical significance. Multilevel analysis showed that abstinence was related to reductions in depressive symptoms.
Conclusions: SCBSCT-BA obtained positive results at short and medium term. Participants who quit smoking experienced a significant reduction in depressive symptoms. Findings support the benefit of adding BA to a cognitive-behavioral smoking cessation treatment. Trial registration www.clinicaltrials.gov NCT02844595.
Idioma: Inglés
DOI: 10.1371/journal.pone.0214252
Año: 2019
Publicado en: PLoS ONE 14, 4 (2019), e0214252[20 pp]
ISSN: 1932-6203
Factor impacto JCR: 2.74 (2019)
Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 27 / 71 = 0.38 (2019) - Q2 - T2
Factor impacto SCIMAGO: 1.023 - Multidisciplinary (Q1)
Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/PSI2015-66755-R
Tipo y forma: Article (Published version)
Área (Departamento): Área Psicología Social (Dpto. Psicología y Sociología)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Exportado de SIDERAL (2022-01-20-22:55:24)
Visitas y descargas
Method: The sample was comprised of 275 adults smokers (61.4% females, mean age = 45.36, SD = 10.96). After baseline assessment sessions, participants were randomized (ratio: 2.2.1.) to SCBSCT-BA, SCBSCT, or WL. Active groups received 8 weekly 1-hour face-to-face group sessions. Biochemically verified smoking abstinence and depressive symptoms were assessed at the end of treatment, and at 3-, 6-, and 12-month follow-ups.
Results: Significant treatment effects in 7-dayspoint prevalence abstinence rates were found for both active groups at the end of treatment. Abstinence rates at 12-months follow-up were 30% for SCBSCT-BA, and 18% for SCBSCT. Using Multiple Imputation for missing data, regression analysis showed significantly greater ORs for the SCBSCT-BA condition (vs. SCBSCT) at the end of treatment and at 3-months follow-up. At 6-, and 12-months follow-ups, ORs for the SCBSCT-BA condition, although greater, did not reach statistical significance. Multilevel analysis showed that abstinence was related to reductions in depressive symptoms.
Conclusions: SCBSCT-BA obtained positive results at short and medium term. Participants who quit smoking experienced a significant reduction in depressive symptoms. Findings support the benefit of adding BA to a cognitive-behavioral smoking cessation treatment. Trial registration www.clinicaltrials.gov NCT02844595.
Idioma: Inglés
DOI: 10.1371/journal.pone.0214252
Año: 2019
Publicado en: PLoS ONE 14, 4 (2019), e0214252[20 pp]
ISSN: 1932-6203
Factor impacto JCR: 2.74 (2019)
Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 27 / 71 = 0.38 (2019) - Q2 - T2
Factor impacto SCIMAGO: 1.023 - Multidisciplinary (Q1)
Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/PSI2015-66755-R
Tipo y forma: Article (Published version)
Área (Departamento): Área Psicología Social (Dpto. Psicología y Sociología)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. Exportado de SIDERAL (2022-01-20-22:55:24)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2019-05-09, last modified 2022-01-20